logo
logo
Sign in

PD1 Resistant Head and Neck Cancer Market Current and Future Projection 2023 to 2033

avatar
Ganesh Shinde
PD1 Resistant Head and Neck Cancer Market Current and Future Projection 2023 to 2033

The global PD1 resistant head & neck cancer market is predicted to be worth US$ 1.54 billion in 2023 and US$ 5 billion by 2033, with a CAGR of 12.5%. The growing geriatric population, as well as the increasing number of initiatives by government and non-governmental organisations such as Support for People with Oral and PD1 Resistant Head and Neck Cancer (SPOHNC), are creating a highly favourable environment for the global PD1 resistant head and neck cancer market to grow.

Immunotherapy is an innovative treatment for cancer, including head and neck, lymphoma, melanoma, and non-small cell lung cancer. Some tumors respond well to traditional therapies such as chemotherapy. In other instances, immunotherapy is combined with conventional cancer therapies to increase the body’s natural defenses against cancer. As part of its regular functionality, the immune system discovers and eliminates aberrant cells, so preventing or stifling the formation of several malignancies. Immune cells, for instance, are occasionally seen in and surrounding tumors. An estimated 75% of head and neck cancers are caused by alcohol and cigarette intake.

However, frequent treatment of cancer of the head and neck involve a mix of radiation and chemotherapy treatment, which results into various adverse effects like hair loss, speech impairment, and loss of natural voice. Additionally, after undergoing cancer surgery, people have difficulty eating. Thus, these factors will restrain market growth.

Competitive Landscape

Key players in the Head and Neck Cancer market are: Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.

Know More Details About Report@ https://www.futuremarketinsights.com/reports/pd1-resistant-head-and-neck-cancer-market

Key Segments Profiled in the PD1 Resistant Head and Neck Cancer Market Industry Survey

PD1 Resistant Head and Neck Cancer Market by Product:

Cytotoxic Agents

  • Antimetabolites
  • Antitubulins
  • Others - Platinum Agents, Fluoropyrimidines

EGFR Inhibitors

  • Erbitux
  • Vectibix
  • Theracim/Theraloc

EGFR Inhibitors

  • Tarceva
  • Tykerb/Tyverb

PD1 Inhibitors

  • Keytruda
  • Opdivo

Pipeline Drugs

  • EGFR Inhibitors
  • PDL1 Inhibitors
  • CTLA4 Inhibitors


collect
0
avatar
Ganesh Shinde
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more